Effect of metformin and simvastatin in treatment of polycystic ovarian syndrome
- Conditions
- Polycystic ovarian syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT20140525017827N8
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 144
oligomenorrhea or amenorrhea
clinical or laboratory findings of hyperandrogenism
existence of polycystic ovaries in ultrasound examination) will be invited to take part in the study
Aging 18-40 years
single
Not suffering from thyroid disorder, Cushing’s syndrome, and hyperprolactinemia
Not having kidney disorder, liver disorder, diabetes, and lipid profile disorder
Not having the history of cardiovascular diseases and hypertension
Not having used ovarian function stimulators or hormonal drugs during the past 3 months
Not having used medications affecting insulin or lipid profiles within the past 3 months
Not smoking
Not consuming alcohol
Not using drugs
Not suffering from breast cancer
Not having medical contraindications
Not having maladaptation
Getting married
Not being willing to continue treatment
Presentation of side effects due to consumption of study medications
Not following the research protocol
Losing weight by 3 kg or more within the past 2 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endocrine parameters (total testosterone, free testosterone, DHEA, estradiol, FSH, LH, SHBG, prolactin, and TSH). Timepoint: before and after intervention. Method of measurement: Eliza Kit.;Metabolic parameters (bilirubin, aminotransferases, total cholesterol, LDL, HDL, TG, fasting glucose, 2-hour glucose tolerance test, fasting insulin, insulin sensitivity index, hs-CRP, sVCAM, and homocysteine). Timepoint: Before and after intervention. Method of measurement: Eliza Kit.
- Secondary Outcome Measures
Name Time Method